Drug Profile


Alternative Names: Solosec; SYM 1219

Latest Information Update: 19 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Symbiomix Therapeutics
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bacterial vaginosis

Most Recent Events

  • 17 Jul 2017 Safety and efficacy data from a phase II trial in Bacterial vaginosis released by Symbiomix Therapeutics
  • 23 Mar 2017 FDA assigns PDUFA action date of (17/09/2017) for secnidazole for Bacterial vaginosis (In adolescents, In adults)
  • 23 Mar 2017 The US FDA accepts NDA for secnidazole for Bacterial vaginosis (In adolescents, In adults) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top